Skip Navigation LinksHome   >   Our Science   >   Our Research Partners

Research Partners

OCT has combined innovation with technical expertise to develop a “fast-track” drug development strategy which includes operating a partnership model with an extensive network of external academic and commercial partners. This approach lowers both developmental risk and costs, and shortens the timeframe to commercialisation without compromising on the crucial safety and efficacy testing required for regulatory approval.

The deal with Canopy Growth Corporation, for example, has quadrupled OCT’s existing proprietary cannabinoid derivative and patent family library which will enhance programmes 3 and 4, while potentially supporting and expanding additional drug development programmes.